Objectives: To describe clinical characteristics of patients with Still's disease treated with methotrexate (MTX) and to assess drug effectiveness evaluating change in disease activity, reduction of inflammatory markers, and glucocorticoid (GC)-sparing effect. Methods: Patients with Still's disease treated with MTX were assessed among those included in AIDA Network Still Disease Registry. Results: In this registry, 171 patients with Still's disease were treated with MTX (males 43.3%, age 37.1 ± 16.0 years). They were mainly characterised by joint features and fever without a prominent multiorgan involvement. MTX was administered with GCs in 68.4% of patients, with other conventional synthetic DMARDs in 6.4%, and with biologic DMARDs in 25.1%. A significant reduction of the modified systemic score was observed, and 38.6% patients were codified as being in clinical remission at the end of follow-up. The concomitant administration of a biologic DMARD resulted a predictor of the clinical remission. Furthermore, a reduction of inflammatory markers and ferritin levels was observed following the administration of MTX. Additionally, a marked reduction of the dosage of concomitant GCs was identified, while 36.7% discontinued such drugs. Male gender appeared as a predictor of GC discontinuation. MTX was discontinued in 12.3% of patients because of adverse effects, and in 12.3% for lack of efficacy. Conclusions: Clinical characteristics of patients with Still's disease treated with MTX were described, mainly joint features and fever without a prominent multiorgan involvement. The clinical usefulness of MTX was reported in reducing the disease activity, decreasing the inflammatory markers, and as GC-sparing agent.

The administration of methotrexate in patients with Still's disease, "real-life" findings from AIDA Network Still Disease Registry

Govoni, Marcello
Membro del Collaboration Group
;
Ruffilli, Francesca
Membro del Collaboration Group
;
2023

Abstract

Objectives: To describe clinical characteristics of patients with Still's disease treated with methotrexate (MTX) and to assess drug effectiveness evaluating change in disease activity, reduction of inflammatory markers, and glucocorticoid (GC)-sparing effect. Methods: Patients with Still's disease treated with MTX were assessed among those included in AIDA Network Still Disease Registry. Results: In this registry, 171 patients with Still's disease were treated with MTX (males 43.3%, age 37.1 ± 16.0 years). They were mainly characterised by joint features and fever without a prominent multiorgan involvement. MTX was administered with GCs in 68.4% of patients, with other conventional synthetic DMARDs in 6.4%, and with biologic DMARDs in 25.1%. A significant reduction of the modified systemic score was observed, and 38.6% patients were codified as being in clinical remission at the end of follow-up. The concomitant administration of a biologic DMARD resulted a predictor of the clinical remission. Furthermore, a reduction of inflammatory markers and ferritin levels was observed following the administration of MTX. Additionally, a marked reduction of the dosage of concomitant GCs was identified, while 36.7% discontinued such drugs. Male gender appeared as a predictor of GC discontinuation. MTX was discontinued in 12.3% of patients because of adverse effects, and in 12.3% for lack of efficacy. Conclusions: Clinical characteristics of patients with Still's disease treated with MTX were described, mainly joint features and fever without a prominent multiorgan involvement. The clinical usefulness of MTX was reported in reducing the disease activity, decreasing the inflammatory markers, and as GC-sparing agent.
2023
Ruscitti, Piero; Sota, Jurgen; Vitale, Antonio; Lopalco, Giuseppe; Iannone, Florenzo; Morrone, Maria; Giardini, Henrique Ayres Mayrink; D'Agostin, Marília Ambuel; Antonelli, Isabelle Parente de Brito; Almaghlouth, Ibrahim; Asfina, Kazi Nur; Khalil, Najma; Sfikakis, Petros P; Laskari, Katerina; Tektonidou, Maria; Ciccia, Francesco; Iacono, Daniela; Riccio, Flavia; Ragab, Gaafar; Hussein, Mohamed A; Govoni, Marcello; Ruffilli, Francesca; Direskeneli, Haner; Alibaz-Oner, Fatma; Giacomelli, Roberto; Navarini, Luca; Bartoloni, Elena; Riccucci, Ilenia; Martín-Nares, Eduardo; Torres-Ruiz, Jiram; Cipriani, Paola; Di Cola, Ilenia; Hernández-Rodríguez, José; Gómez-Caverzaschi, Verónica; Dagna, Lorenzo; Tomelleri, Alessandro; Makowska, Joanna; Brzezinska, Olga; Iagnocco, Annamaria; Bellis, Elisa; Caggiano, Valeria; Gaggiano, Carla; Tarsia, Maria; Mormile, Ilaria; Emmi, Giacomo; Sfriso, Paolo; Monti, Sara; Erten, Şükran; Del Giudice, Emanuela; Lubrano, Riccardo; Conti, Giovanni; Olivieri, Alma Nunzia; Lo Gullo, Alberto; Tharwat, Samar; Karamanakos, Anastasios; Gidaro, Antonio; Maggio, Maria Cristina; La Torre, Francesco; Cardinale, Fabio; Ogunjimi, Benson; Maier, Armin; Sebastiani, Gian Domenico; Opris-Belinski, Daniela; Frassi, Micol; Viapiana, Ombretta; Bizzi, Emanuele; Carubbi, Francesco; Fotis, Lampros; Tufan, Abdurrahman; Kardas, Riza Can; Więsik-Szewczyk, Ewa; Jahnz-Różyk, Karina; Fabiani, Claudia; Frediani, Bruno; Balistreri, Alberto; Rigante, Donato; Cantarini, Luca
File in questo prodotto:
File Dimensione Formato  
The administration of methotrexate in patients with Still_s disease, real-life findings from AIDA Network Still Disease Registry.pdf

accesso aperto

Tipologia: Full text (versione editoriale)
Licenza: Creative commons
Dimensione 1.29 MB
Formato Adobe PDF
1.29 MB Adobe PDF Visualizza/Apri

I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/2545490
Citazioni
  • ???jsp.display-item.citation.pmc??? 2
  • Scopus 4
  • ???jsp.display-item.citation.isi??? 3
social impact